Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with HER2-positive breast cancer, according to long-term results of a randomized phase 3 trial. Ado-trastuzumab emtansine (Kadcyla, Genentech) — often referred to as T-DM1 — also continued to show durable benefit for reducing invasive recurrence, long-term results of the
In the phase 3 ECHO trial, acalabrutinib with bendamustine and rituximab reduced the risk of disease progression or death by 27% compared with standard-of-care chemoimmunotherapy.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Investigators in the Clinical Genetics Branch, led by senior investigator Lisa Mirabello and former research fellow Maísa Pinheiro, used deep targeted sequencing to look for…
In this issue of Cancer Cell, Son et al. highlight an unexpected role for skin β-papillomaviruses in the protection against skin carcinogenesis. T cell immunity to skin…
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received…
Datopotamab deruxtecan-dlnk received approval from the FDA for previously treated unresectable or metastatic, HR-positive, HER2-negative breast cancer.
An abstract is unavailable.
Study also finds socioeconomic status linked to brain health in adults
On Jan. 15, 2025, the FDA approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for KRAS G12C-mutated metastatic colorectal cancer.
